SIETES :: 93083 citas

Resultados de la búsqueda por FASE II REFINAR BÚSQUEDA

1.

Parsons L. Novavax reports promising phase 1 results for coronavirus vaccine. PMLiVE 2020:5 de agosto. [Ref.ID 103702]

2.

Parsons L. AZ/Oxford’s COVID-19 vaccine proves promising in early trials. Vaccine candidate produced robust immune response. PMLiVE 2020:21 de julio. [Ref.ID 103692]

3.

Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al.. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020:1. [Ref.ID 103691]

4.

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020:20 de julio. [Ref.ID 103690]

5.

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough P, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, et al. for the mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med 2020:14 de julio. [Ref.ID 103684]

6.

Mullard A. COVID-19 vaccine development pipeline gears up. Lancet 2020:6 de junio. [Ref.ID 103658]

7.

PMG Group. Imperial College London pledges low-cost access to COVID-19 vaccine. PMLiVE 2020:8 de junio. [Ref.ID 103657]

8.

PMGroup. AZ secures capacity for one billion coronavirus vaccine doses. Initial agreement to supply 400 million doses of Oxford University’s vaccine. PMLiVE 2020:21 de mayo. [Ref.ID 103648]

9.

Taylor P. Novavax COVID-19 vaccine bags record $384m funding from CEPI. PMLiVE 2020:12 de mayo. [Ref.ID 103623]

10.

Corbella J. La primera vacuna de la Covid ensayada en personas muestra eficacia. La Vanguardia 2020:19 de mayo. [Ref.ID 103619]

11.

Samper E. Lo que el dinero no puede acelerar: ¿Por qué requiere tanto tiempo conseguir una vacuna contra el coronavirus? . eldiario.es 2020:9 de mayo. [Ref.ID 103617]

12.

PM Group. Developing a COVID-19 vaccine. PMLiVE 2020:28 de abril. [Ref.ID 103606]

13.

PMG Group. Moderna submits application to advance coronavirus vaccine testing. PMLiVE 2020:28 de abril. [Ref.ID 103605]

14.

Abrams DI, Guzmán M. Can cannabis cure cancer?1. JAMA Oncology 2020:1. [Ref.ID 103508]

15.

Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2018;18:febrero. [Ref.ID 102909]

16.

Taylor P. GSK’s says depot HIV injection works over three years. The injection could rival Gilead’s single-tablet therapy. PMLiVE 2018:30 de octubre. [Ref.ID 102836]

17.

Begley S. ‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims — and finding some truth. STAT 2018:23 de agosto. [Ref.ID 102810]

18.

Fuentes Camps I, Rodríguez A, Agustí A. Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102808]

19.

Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet 2018;391:30 de junio. [Ref.ID 102741]

20.

Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]